Discovery of pyrrolopyridazines as novel DGAT1 inhibitors was written by Fox, Brian M.;Iio, Kiyosei;Li, Kexue;Choi, Rebeka;Inaba, Takashi;Jackson, Simon;Sagawa, Shoichi;Shan, Bei;Tanaka, Masahiro;Yoshida, Atsuhito;Kayser, Frank. And the article was included in Bioorganic & Medicinal Chemistry Letters in 2010.HPLC of Formula: 22808-29-3 This article mentions the following:
A new structural class of DGAT1 inhibitors was discovered and the structure-activity relationship was explored. The pyrrolotriazine core of the original lead mol. was changed to a pyrrolopyridazine core providing an increase in potency. Further exploration resulted in optimization of the Pr group at C7 and the discovery that the ester at C6 could be replaced by five-membered heterocyclic rings. The analogs prepared have DGAT1 IC50 values ranging from >10 渭M to 48 nM. In the experiment, the researchers used many compounds, for example, 4-tert-Butyl-3,6-dichloropyridazine (cas: 22808-29-3HPLC of Formula: 22808-29-3).
4-tert-Butyl-3,6-dichloropyridazine (cas: 22808-29-3) belongs to pyridazine derivatives. Pyridazine-based compounds continued to be a great source of biologically active compounds as evidenced by the number of publications which emerged in 2021. Pyridazine and derivatives coordinate readily with transition metals to form complexes and catalysts with synthetic utility.HPLC of Formula: 22808-29-3
Referemce:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2 – PubChem